Tenax Therapeutics (NASDAQ:TENX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research report released on Wednesday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Price Performance

Shares of NASDAQ:TENX opened at $3.39 on Wednesday. The stock has a 50 day moving average price of $3.32 and a 200-day moving average price of $4.84. Tenax Therapeutics has a 52-week low of $2.77 and a 52-week high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last released its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.72). On average, equities analysts anticipate that Tenax Therapeutics will post -7.96 earnings per share for the current fiscal year.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.